<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262730</url>
  </required_header>
  <id_info>
    <org_study_id>NABTT-0501</org_study_id>
    <secondary_id>U01CA062475</secondary_id>
    <secondary_id>NABTT-0501 CDR0000454915</secondary_id>
    <secondary_id>NA_00001963</secondary_id>
    <nct_id>NCT00262730</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM</brief_title>
  <official_title>A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
      chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Biological therapies, such as
      poly ICLC, may stimulate the immune system in different ways and stop tumor cells from
      growing. Giving poly ICLC after radiation therapy and temozolomide may stop any remaining
      tumor cells from growing.

      PURPOSE: This phase II trial is studying how well giving radiation therapy together with
      temozolomide followed by temozolomide and poly ICLC works in treating patients with newly
      diagnosed glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the safety and efficacy of radiation plus low-dose temozolomide followed by
           adjuvant temozolomide and intramuscular poly ICLC for adult patients with newly
           diagnosed glioblastoma multiforme.

      Secondary

        -  Estimate the frequency of toxicity associated with this treatment regimen.

      OUTLINE: This is an open-label, multicenter study.

        -  Induction chemoradiotherapy: Patients undergo radiotherapy once daily, 5 days a week,
           for 6 weeks. During the same 6 weeks, patients also receive oral temozolomide once
           daily. Four weeks later, patients are evaluated for disease progression. Patients with
           progressive disease are removed from the study. Patients with no progressive disease
           proceed to maintenance therapy.

        -  Maintenance therapy: Patients receive oral temozolomide once daily on days 1-5 (week 1).
           Patients also receive poly ICLC intramuscularly three times a week in weeks 2-8. Courses
           repeat every 9 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study therapy, patients are followed every 2 months for survival.

      PROJECTED ACCRUAL: A total of 96 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 months</time_frame>
    <description>survival time is defined from time of histological diagnosis to death occurrence.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT + TMZ 6wks, followed by
poly ICLC, temozolomide, radiation: radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>poly ICLC</intervention_name>
    <description>20 mcg/kg 3x each week (Maintenance cycles)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Holtonol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>RT: 60 Gy (6 weeks) concomitant therapy</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)
             by biopsy or resection within the past 3 months

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status ≥ 60%

          -  Absolute neutrophil count ≥ 1500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin ≤ 1.5 mg/dL

          -  Transaminases ≤ 4 times above the upper limits of the institutional normal

          -  Creatinine ≤ 1.7 mg/dL

          -  Not pregnant or breast-feeding

          -  Patients must agree to follow acceptable birth control methods to avoid conception

          -  Negative pregnancy test

          -  Patients must have a Mini Mental State Exam score of ≥ 15

          -  No serious concurrent infection or medical illness which would jeopardize the ability
             of the patient to receive the treatment outlined in this protocol with reasonable
             safety

          -  Patients with a concurrent or prior malignancy are ineligible unless they are patients
             with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin

               -  Patients who have been free of disease (any prior malignancy) for ≥ five years
                  are eligible for this study

          -  Patients requiring ongoing therapy for psychoses with antipsychotic medications at the
             time of enrollment will be ineligible

        PRIOR CONCURRENT THERAPY:

          -  Patients must not have received prior radiation therapy, chemotherapy, immunotherapy
             or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense,
             peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or
             hormonal therapy for their brain tumor

               -  Prior glucocorticoid therapy is allowed

          -  Patients must be willing to forego other cytotoxic and non-cytotoxic drug therapy
             against the tumor while being treated with poly ICLC plus temozolomide on this
             protocol

          -  No other concurrent therapy for their tumor (i.e., chemotherapeutics or
             investigational agents)

          -  Patients who have received prior Gliadel wafers are not eligible for this study

          -  No concurrent prophylactic filgrastim (G-CSF)

          -  No concurrent electron, particle, implant, or stereotactic radiosurgery boost
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myrna Rosenfeld, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 2010 Oct;12(10):1071-7. doi: 10.1093/neuonc/noq071. Epub 2010 Jul 8.</citation>
    <PMID>20615924</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <results_first_submitted>March 22, 2013</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>outpatient clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm - All Subjects</title>
          <description>poly ICLC, temozolomide, radiation: radiation therapy
poly ICLC : 20 mcg/kg 3x each week (Maintenance cycles)
temozolomide : daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
radiation therapy : RT: 60 Gy (6 weeks) concomitant therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm - All Subjects</title>
          <description>poly ICLC, temozolomide, radiation: radiation therapy
poly ICLC : 20 mcg/kg 3x each week (Maintenance cycles)
temozolomide : daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
radiation therapy : RT: 60 Gy (6 weeks) concomitant therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" lower_limit="21" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status</title>
          <description>100 normal no complaints no disease 90 capable of normal activity few symptoms/disease 80 normal activity with some difficulty some symptoms or signs 70 caring for self not capable of normal activity or work 60 requiring some help can take care of most personal requirements 50 requires help often requires frequent medical care 40 disabled requires special care and help 30 severely disabled hospital admission indicated but no risk of death 20 very ill urgently requiring admission requires supportive measures or treatment 10 moribund rapidly progressive fatal disease processes 0 death</description>
          <units>Units on a scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of surgery</title>
          <units>Patient</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craniotomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>time from diagnosis to radiotherapy</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" lower_limit="2" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Mini-Mental State Examiniation (MMSE) Score</title>
          <description>The mini–mental state examination (MMSE) is a 30-point questionnaire test used to screen for cognitive impairment. Commonly used to screen for dementia. It is also used to estimate the severity of cognitive impairment and to follow the course of cognitive changes in an individual over time. The MMSE test includes simple questions and problems in a number of areas: the time and place of the test, repeating lists of words, arithmetic such as the serial sevens, language use and comprehension, and basic motor skills. The Higher your score, the higher your function.</description>
          <units>Scores on a Scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27-29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than or equal 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corticosteroid Therapy</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic Diagnosis</title>
          <units>Patient</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Glioblastoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaplastic Astrocytoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>survival time is defined from time of histological diagnosis to death occurrence.</description>
        <time_frame>30 months</time_frame>
        <population>all patients who were treated were analyzed (intent to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm - All Subjects</title>
            <description>poly ICLC, temozolomide, radiation: radiation therapy
poly ICLC : 20 mcg/kg 3x each week (Maintenance cycles)
temozolomide : daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
radiation therapy : RT: 60 Gy (6 weeks) concomitant therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>survival time is defined from time of histological diagnosis to death occurrence.</description>
          <population>all patients who were treated were analyzed (intent to treat)</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="15.4" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>study design has 85% power to detect 25% deduction in hazard rate compared to EORTC Phase 3 results.</non_inferiority_desc>
            <p_value>&gt;.1</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While on Treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm All Subjects</title>
          <description>poly ICLC, TMZ, RT: poly ICLC : 20 mcg/kg 3x each week (Maintenance cycles) TMX : daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant) RT : RT: 60 Gy (6 weeks) concomitant therapy
AEs Grades 4 with Attributions of Possible, probably or definitely related to TMZ AND poly-ICLI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hemoglobin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness, generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <description>desquamation</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="760" subjects_affected="71" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hemoglobin increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>leukocytes</sub_title>
                <description>total white blood cell count</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>PLTS</sub_title>
                <counts group_id="E1" events="468" subjects_affected="59" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>PO4</sub_title>
                <counts group_id="E1" events="31" subjects_affected="19" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>pain - cardiac/heart/chest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>supraventricular and nodal arrhythmia</sub_title>
                <description>atrial fibrillation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>supraventricular and nodal arrhythmia</sub_title>
                <description>atrial tachycardia/paroxysmal atrial tachycardia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>supraventricular and nodal arrhythmia</sub_title>
                <description>sinus tachycardia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear and labyrinth disorder</sub_title>
                <description>other</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hearing</sub_title>
                <description>w/o baseline audiogram &amp; no monitoring program</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>otitis</sub_title>
                <description>external ear, middle ear</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - external ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - middle ear</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>cushingoid</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>endocrine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>dry eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>ocular/vision disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>diplopia (double vision)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>photosensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>vision - blurred</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>vision - flashing lights/floaters</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>watery eye</sub_title>
                <description>epiphora, tearing</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="52" subjects_affected="38" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>periodontal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>distension/bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>mucositis oral</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="64" subjects_affected="41" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - abdomen</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - dental/teeth/peridontal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - stomach</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>taste alteration</sub_title>
                <description>dysgeusia</description>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>ulceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <description>head and neck</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <description>limbs</description>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="112" subjects_affected="70" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <description>in absence of neutropenia</description>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>flu like symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - chest/thorax</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>rigors/chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>syndromes - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>International Normalized Ratio of prothrombin time</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>esophageal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <description>bladder (urinary)</description>
                <counts group_id="E1" events="45" subjects_affected="42" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>injury</sub_title>
                <description>intra-operative brain injury</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <description>associated with radiation (chemoradiation &amp; radiation)</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="66" subjects_affected="19" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>SGOT/AST</sub_title>
                <counts group_id="E1" events="37" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>SGPT/ALT</sub_title>
                <counts group_id="E1" events="131" subjects_affected="34" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>total bilirubin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>white blood cells</sub_title>
                <counts group_id="E1" events="793" subjects_affected="64" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="28" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="246" subjects_affected="65" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="15" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypermagnesemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>uric acid</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>extremity - lower (gait/walking)</sub_title>
                <description>gait disturbance</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>joint function</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>lumbar spine range of motion decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>muscle weakness, generalized or specific area</sub_title>
                <counts group_id="E1" events="43" subjects_affected="33" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>soft tissue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - back</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - extremity</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - joint</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - muscle</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - neck</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ataxia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>cognitive disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hemorrhage</sub_title>
                <description>CNS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hydrocephalus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>memory impairment</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>neurological disorder</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>neuropathy</sub_title>
                <counts group_id="E1" events="80" subjects_affected="58" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="80" subjects_affected="51" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pyramidal tract dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="68" subjects_affected="34" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>speech impairment</sub_title>
                <description>dysphasia or aphasia</description>
                <counts group_id="E1" events="34" subjects_affected="22" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>libido decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>mood alteration</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>personality/behavioral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>psychosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hemorrhage</sub_title>
                <description>urinary</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>obstruction</sub_title>
                <description>ureter, bladder</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pain - breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>allergic rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hemorrhage</sub_title>
                <description>nose</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>paranasal sinus reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>voice changes</sub_title>
                <description>hoarseness, loss or alteration in voice, laryngitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatology/skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>nail changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - scalp</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pain - skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>pruritus/itching</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>purpura</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>rash - acneiform</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>rash - desquamation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hot flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>vascular - other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>&quot;Other Adverse Events&quot; not reported for this study. Only serious(grade 3/4)related to either TMZ and/or Poly were reported. Subjects may have experienced grade 1 and grade 2 other adverse event but they have no bearing on clinical outcome of agent</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Adult Brain Tumor Consortium</name_or_title>
      <organization>Adult Brain Tumor Consortium Central Office- Johns Hopkins</organization>
      <phone>410-955-3657</phone>
      <email>jfisher@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

